• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Eye Care Launch Chaos





Well since the last 360 was performed on DD and everyone on his team bashed him- he probably cried like a little baby and so now the 360s are dead in the water. What a shame because more managers at this company need to know how horrible they are at their jobs.
 








































The layoffs should start with the pathetic leadership who botched this launch. From the moment Vuity was approved, it’s been utter chaos. And what’s worse is they keep acting like everything is smooth sailing.

Why is the sales force always the one getting canned when we’re just taking direction from the morons at the top?
 
















We were told Q1 it would be TMOT based. So the larger volume territories would continue to do well. Funny that the smaller volume are at the top of the ranks. Don’t even get me started on P2 and P3 fulfillment and access to numbers. The management of this launch is another failed execution and the reps are the only ones suffering for all their continual hard work despite lack of direction from top down. No reps are making the money they should be. Maybe our base salaries should be adjusted to those in other eye care divisions. Those with lower quotas and I is Al numbers to hit just to contour getting paid over $150K while we in pharma are fronting the bill for the other divisions. The efforts from us are not being matched in dollars and the turnover will show (and already has). Those doing well are not being rewarded and those territories which are not aren’t even being given the chance to earn with factors out of our control for all products in our bag.
 




We were told Q1 it would be TMOT based. So the larger volume territories would continue to do well. Funny that the smaller volume are at the top of the ranks. Don’t even get me started on P2 and P3 fulfillment and access to numbers. The management of this launch is another failed execution and the reps are the only ones suffering for all their continual hard work despite lack of direction from top down. No reps are making the money they should be. Maybe our base salaries should be adjusted to those in other eye care divisions. Those with lower quotas and I is Al numbers to hit just to contour getting paid over $150K while we in pharma are fronting the bill for the other divisions. The efforts from us are not being matched in dollars and the turnover will show (and already has). Those doing well are not being rewarded and those territories which are not aren’t even being given the chance to earn with factors out of our control for all products in our bag.

P2 products numbers? I don't even get numbers for my biggest Restasis writers anymore... it's a complete joke.
 




And how do we even know the P2 and P3 numbers are correct with data to back it up? We could be getting paid on TMOTs which may not even be correct. We don’t just sell ONE PRODUCT!
 




And how do we even know the P2 and P3 numbers are correct with data to back it up? We could be getting paid on TMOTs which may not even be correct. We don’t just sell ONE PRODUCT!

The fact that our top P2 writers have been taken out of Advance is beyond shady, but not surprising

Lets be honest here, have the voodoo Advance numbers at allergan ever been accurate?

Does anyone remember the conference call with DG telling everyone they had to "adjust" rankings after literally no one in eyecare was above 100% attainment for the quarter?

Then the recent Q4 bonus adjustment that happened weeks after payout, and it took a *DM* to see that the numbers weren't calculated correctly...odd

How about when the Blue reps rankings magically changed last quarter right before the final IC came out?... And lets not forget that it's the ALWAYS the same territories that make PC year after year

..why would anyone trust "data" that comes from this company?
 




The fact that our top P2 writers have been taken out of Advance is beyond shady, but not surprising

Lets be honest here, have the voodoo Advance numbers at allergan ever been accurate?

Does anyone remember the conference call with DG telling everyone they had to "adjust" rankings after literally no one in eyecare was above 100% attainment for the quarter?

Then the recent Q4 bonus adjustment that happened weeks after payout, and it took a *DM* to see that the numbers weren't calculated correctly...odd

How about when the Blue reps rankings magically changed last quarter right before the final IC came out?... And lets not forget that it's the ALWAYS the same territories that make PC year after year

..why would anyone trust "data" that comes from this company?

Why is there so many changes and ambiguity with the payouts and numbers? Are we even getting scorecards anymore? Is this elementary basketball where every participant gets a trophy and the same bonus pay out? So much shady stuff combined with silence from above. Do they just want us to leave???
 




Similar threads